Lytic Activity of Polyvalent Staphylococcal Bacteriophage PhiSA012 and Its Endolysin Lys-PhiSA012 Against Antibiotic-Resistant Staphylococcal Clinical Isolates From Canine Skin Infection Sites
Lytic Activity of Polyvalent Staphylococcal Bacteriophage PhiSA012 and Its Endolysin Lys-PhiSA012 Against Antibiotic-Resistant Staphylococcal Clinical Isolates From Canine Skin Infection Sites
复制标题
DOI：
10.3389/fmed.2020.00234
复制
发表时间：
2020-06-10
影响因子：
3.9
通讯作者：
Iwanol, Hidetomo
中科院分区：
文献类型：
--
作者：
Nakamura, Tomohiro;Kitana, Junya;Iwanol, Hidetomo
耐药性细菌（ARB）在人类和兽医学中的传播是全球关注的问题。值得注意的是，耐甲氧西林假中间葡萄球菌的出现已经成为一个严重的问题。在这种情况下，噬菌体及其裂解酶，内溶素，作为替代抗生素的感染性疾病的治疗剂已经受到相当大的关注。本研究的目的是调查从日本东京一家初级保健动物医院的犬皮肤中分离的葡萄球菌的耐药性模式，并评估葡萄球菌噬菌体phiSA 012及其内溶素Lys-phiSA 012对分离的耐药性葡萄球菌菌株的裂解活性。从犬感染部位分离出40份临床葡萄球菌样品（20份来自皮肤，20份来自外耳道）。药敏试验采用纸片扩散法。通过使用针对葡萄球菌分离株的斑点试验确定phiSA 012的宿主范围。针对对五类或更多抗微生物剂显示耐药性的葡萄球菌分离株，使用浊度降低测定法评价phiSA 012和Lys-phiSA 012的裂解活性。23岁从犬皮肤和耳道感染中检出假中间型葡萄球菌16株，施氏葡萄球菌16株，中间型葡萄球菌1株，其中耐甲氧西林的假中间型葡萄球菌占43.5%，施氏葡萄球菌占31.3%。此外，多药耐药（MDR）S。假中间型占65.2%。PhiSA 012对所有的葡萄球菌都有感染作用，但对MDRS的溶解活性很低。假中间体另一方面，Lys-phiSA 012显示裂解活性，并显著减少葡萄球菌菌落形成单位的数量。这些结果表明，ARB的问题，潜在的小动物医院和建议的替代抗生素。Lys-phiSA 012对葡萄球菌分离株具有比phiSA 012更广泛的裂解活性;因此，Lys-phiSA 012是用于包括犬皮肤的几种葡萄球菌感染的更有潜力的候选治疗剂。
The spread of antibiotic-resistant bacteria (ARB) in human and veterinary medicine is of global concern. Notably, the emergence of methicillin-resistantStaphylococcus pseudintermediushas become a serious problem. In this context, bacteriophages and their lytic enzymes, endolysins, have received considerable attention as therapeutics for infectious diseases in place of antibiotics. The aim of the present study was to investigate the antibiotic-resistance patterns of staphylococcal species isolated from canine skin at a primary care animal hospital in Tokyo, Japan and evaluate the lytic activity of the staphylococcal bacteriophage phiSA012 and its endolysin Lys-phiSA012 against isolated antibiotic-resistant staphylococcal strains. Forty clinical staphylococcal samples were isolated from infection sites of dogs (20 from skin and 20 from the external ear canal). Susceptibility to antimicrobial agents was determined by a disk diffusion method. The host range of phiSA012 was determined by using a spot test against staphylococcal isolates. Against staphylococcal isolates that showed resistance toward five classes or more of antimicrobials, the lytic activity of phiSA012 and Lys-phiSA012 was evaluated using a turbidity reduction assay. Twenty-threeS. pseudintermedius, 16Staphylococcus schleiferi, and 1Staphylococcus intermediuswere detected from canine skin and ear infections, and results revealed 43.5% methicillin resistance inS. pseudintermediusand 31.3% inS. schleiferi. In addition, the prevalence multidrug resistance (MDR)S. pseudintermediuswas 65.2%. PhiSA012 could infect all staphylococcal isolates by spot testing, but showed little lytic activity by turbidity reduction assay against MDRS. pseudintermediusisolates. On the other hand, Lys-phiSA012 showed lytic activity and reduced significantly the number of staphylococcal colony-forming units. These results demonstrated that ARB issues underlying in small animal hospital and proposed substitutes for antibiotics. Lys-phiSA012 has broader lytic activity than phiSA012 against staphylococcal isolates; therefore, Lys-phiSA012 is a more potential candidate therapeutic agent for several staphylococcal infections including that of canine skin.